



**CHARITY COMMISSION  
FOR ENGLAND AND WALES**

**Trustees' Annual Report for the period**

From	Period start date			To	Period end date		
	Day	Month	Year		Day	Month	Year
	23	June	2024		22	June	2025

Charity name	Radiotherapy UK
Other names charity is known by	ACCORN Action Radiotherapy
Charity registration number	1135902

**Objectives and Activities**

	SORP reference	
Summary of the purposes of the charity as set out in its governing document	Para 1.17	<ol style="list-style-type: none"><li><b>To promote, support and encourage research into radiotherapy, radiobiology and allied subjects, and the dissemination of the useful results of such research by such actions as:</b><ol style="list-style-type: none"><li>Promoting and facilitating multidisciplinary collaboration between researchers and practitioners in radiotherapy and its allied subjects</li><li>Informing patients and the public about practice and research in radiotherapy and its allied subjects, and engaging patients and the public in the development of research projects</li><li>Awarding grants as appropriate</li></ol></li><li><b>To advance and benefit the practice of radiotherapy and its allied subjects to relieve sickness and preserve good health by such actions as:</b><ol style="list-style-type: none"><li>Promoting and facilitating multidisciplinary networking and sharing of expertise and best practice</li><li>Promoting and encouraging the study of the science and practice of radiotherapy and its allied subjects</li><li>Promoting and facilitating increased involvement of allied professions</li><li>Facilitating development and dissemination of best practices in radiotherapy and its allied subjects</li><li>Disseminating knowledge concerning all aspects of the science and practice of radiotherapy and its allied subjects</li><li>Promoting and facilitating education and training in the research and practice of radiotherapy and its allied subjects</li></ol></li></ol>

<p><b>Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts.</b></p>	<p>Para 1.17 and 1.19</p>	<p><i>1. Patient information resources</i></p> <p>We work to support patients with cancer through the provision of trusted, accessible and relevant information resources before, during and following their radiotherapy treatment. We develop Patient Information Forum (PIF) accredited resources that means patients and families can trust that what we produce is evidence-based, understandable, jargon-free, up-to-date and produced to the best possible standard.</p> <p><i>2. Advocacy and Campaigning</i></p> <p>We work in partnership with patients, academics, workforce, industry and parliamentarians to campaign for equality of access to world-class radiotherapy for all patients with cancer in the UK. We raise awareness of how harnessing technologically advanced, cost-effective radiotherapy could treat more patients, quicker.</p> <p>We are proud to be the charity partner of the <a href="#">Radiotherapy4Life</a> campaign and co-founder of the <a href="#">#CatchUpWithCancer</a> campaign. As Secretariat for the APPG-Radiotherapy we work with the Chair and Officers in organising events, meetings and ensuring all APPG regulations and requirements are met.</p> <p>Our work also has global reach through our partnership with the Global Coalition for Radiotherapy as we support other countries advocating for increased access to radiotherapy services.</p> <p><i>3. Workforce engagement and support</i></p> <p>Our work amplifies the voice of the frontline radiotherapy workforce to raise awareness of the issues faced in the delivery of services. We provide opportunities for the workforce to learn and engage with ideas, innovations and technologies that can support them in developing patient-centred care and practice. We offer an active network of radiotherapy professionals who offer peer support, education and insight. We also promote careers in radiotherapy through job listings shared daily through our platforms and website.</p> <p><i>4. General fundraising/events</i></p> <p>The charity raises funds from a variety of sources including online giving, community events, corporate partnerships, legacies, individual donations and grants. The charity was very grateful to receive support in this financial year from B-Clear, Ergea, Brainlab, Elekta, Varian-Siemens-Healthineers, FlenHealth, Amethyst, AstraZeneca, Price-Jones, Accuray and the Openworks Foundation.</p> <p><i>5. Research and Data</i></p> <p>The charity delivers analysis on publicly available data such as waiting-times for cancer treatment and produces evidence-based reports and research to better understand how radiotherapy services are currently being delivered and what needs to change to improve patient outcomes and</p>
--	---------------------------	---

		<p>experience.</p> <p>We collaborate and support research partners to co-design and deliver patient-focused research projects.</p>
4	Para 1.18	<p>Radiotherapy UK has had regard to the guidance issued by the Charity Commission on public benefit.</p> <p>Radiotherapy UK is committed to making available to the public, information regarding radiotherapy treatment and its benefits, providing opportunities for radiotherapy professionals to share information as well as campaign for better funding for radiotherapy treatment in the UK.</p>

### Additional information (optional)

You may choose to include further statements where relevant about:

Contribution made by volunteers	Para 1.38	<p>Volunteers are essential to our charity's success in delivering services. We depend on them to lead our organization through the Board, and to guide our efforts via the Ambassadors network, as well as patient and clinical engagement groups.</p>
---------------------------------	-----------	---

### Achievements and Performance

	SORP reference	
Summary of the main achievements of the charity, identifying the difference the charity's work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole.	Para 1.20	<p><u>In addition to the activities noted above</u>, the charity has achieved the following this year for the benefit of patients, professionals, and the wider community:</p> <p><b>Advocacy and Policy</b></p> <ul style="list-style-type: none"> <li>We co-ordinated three high-profile events at Westminster, engaging over 75 MPs through our <i>#CatchUpWithCancer</i> and <i>Radiotherapy4Life</i> campaigns.</li> <li>A major milestone was our <a href="#">#CatchUpWithCancer Day in Parliament</a> on World Cancer Day 2025, bringing together over 20 cancer charities and earning national media coverage for our analysis revealing that more than 500,000 people have faced excessive delays in cancer treatment over the past decade.</li> <li>In Autumn 2025, the <a href="#">government announced £70 million</a> for replacing radiotherapy machines, reflecting with one of our campaign's key calls to action.</li> <li>We amplified our advocacy work at four major conferences, presenting nationally and internationally—including UKIO, the SCOR Annual Conference, and an International Cancer Expert Corps event at CERN, Switzerland.</li> <li>The charity supported the development of the world's first <a href="#">World Radiotherapy Awareness Day</a></li> </ul>

		<p>(WRAD). Developed in partnership with founding organisation Global Coalition for Radiotherapy, the day highlighted the need for national and international advocacy to improve access to radiotherapy for all patients globally.</p> <ul style="list-style-type: none"><li>• Parliamentary engagement included 130 Written Questions and one dedicated debate on Accessibility to Radiotherapy on World Cancer Day 2025.</li><li>• Our <i>CatchUpWithCancer</i> petition surpassed 624,919 signatures on <a href="#">change.org petition</a>.</li><li>• We launched our landmark report, <a href="#">Unlocking Modern Radiotherapy</a>, providing critical analysis and recommendations to transform patient access.</li><li>• Radiotherapy UK continued as secretariat for the <a href="#">All-Party Parliamentary Group for Radiotherapy</a> (APPG-RT). Following the election of a new government, the APPG was successfully reconstituted, ending the period with 41 MP members.</li></ul> <p><b>Patient Information</b></p> <ul style="list-style-type: none"><li>• Launched our <a href="#">Patients and Families Online Hub</a> – a major milestone packed with resources to support patients and their loved ones throughout the radiotherapy pathway.</li><li>• Successfully renewed our PIF TICK accreditation following rigorous independent assessment – maintaining our status as a <i>trusted information creator</i> and holding the UK’s only assessed quality mark for health and care information.</li><li>• Created over 45 new patient information resources, ensuring clarity and accessibility for those navigating treatment.</li><li>• Hosted 8 meetings of our Patient Engagement Group, strengthening patient voice in our work.</li><li>• Engaged 10 patient reviewers and 20 clinical reviewers to support the development of high-quality patient information resources.</li><li>• Our new Patients and Families Online Hub have driven significant increase in visits to our website with 56,000 new users over this period, representing a 40% increase in new users from previous period.</li><li>• We are project partners of the GRACE project, (Gynae Radiotherapy Consent Enhancement), research led by Lancaster and Bangor universities and funded by NIHR. GRACE aims to improve how patients make informed decisions about radiotherapy for gynaecological cancer, with input from clinical experts, researchers, those with lived experience and the public.</li></ul>
--	--	--

		<p><b>Workforce Engagement</b></p> <ul style="list-style-type: none"><li>• Delivered four RTUK Talks webinars, attracting 1,221 registrations and generating 479 YouTube views, providing valuable learning and networking opportunities for the radiotherapy workforce.</li><li>• Expanded our Workforce Ambassadors programme, now engaging 50 ambassadors who champion best practice and workforce development across the UK.</li><li>• Launched the 2024 Flash Workforce Survey, with responses from just under 10% of the workforce, helping to inform and strengthen our advocacy work by amplifying the voice of frontline professionals.</li></ul> <p><b>Communications and Awareness</b></p> <ul style="list-style-type: none"><li>• Maintained a strong media presence, with regular coverage in national news and major print publications. <i>(All coverage is available <a href="#">here</a>.)</i></li><li>• Significant growth across key digital channels, in line with our communications strategy:<ul style="list-style-type: none"><li>○ Daily News: 1,964 subscribers</li><li>○ Instagram: 22% increase in followers (from 2,538 to 3,100)</li><li>○ LinkedIn: 24.3% growth (from 6,554 to 8,153 followers)</li><li>○ Facebook: 6.5% growth (from 2,538 to 3,100 followers)</li></ul></li><li>• Website traffic surged, with a 40% increase in new users, reaching 56,000.</li><li>• YouTube engagement grew, with 9,406 views and 485.9 watch hours, expanding our reach through video content.</li></ul> <p><b>Governance</b></p> <ul style="list-style-type: none"><li>• Recruited six new Board members, bringing fresh expertise and perspectives to strengthen leadership and oversight.</li><li>• Developed the 2025–2028 Strategic Plan, setting a clear roadmap for growth, impact, and sustainability.</li></ul>

**Additional information (optional)**

You may choose to include further statements where relevant about:

Achievements against objectives set	Para 1.41	N/A
Performance of fundraising activities against objectives set	Para 1.41	N/A
Other		<p>Corporate Partnerships</p> <p>The charity benefits from several corporate partnerships for example Varian (Siemens Healthineers) and Ergea co-sponsor the charity's Daily News bulletin. All these partnerships are agreed on a vendor neutral basis.</p>

**Financial Review**

Review of the charity's financial position at the end of the period	Para 1.21	<p>The Charity's total income for this financial year was £214,611. Total expenditure for this year was £201,658 leaving the charity with a year-end net profit of £12,953</p> <p>During 2024/2025 The Charity has managed to continue its work within budget by using its contacts and generous donations in kind (resources) from Price Jones Ltd.</p> <p>With the current economic constraints and cost of living crisis this is a challenging time for charity income generation. However, the charity is confident that there are untapped avenues of funding available to the organisation. In this year the charity hired a part-time fundraiser to support with accessing this funding.</p>
Statement explaining the policy for holding reserves stating why they are held	Para 1.22	Radiotherapy UK's policy is to provide the charity with adequate financial stability and the means for it to meet its charitable objectives. Except for such funds as the Trustees consider prudent to maintain for the purposes of management and administration of the charity for the foreseeable future, all unrestricted funds are used to the purpose of general objects of the charity. The adequacy of the reserves is reviewed annually.
Amount of reserves held	Para 1.22	£163,577 (excluding the related party loan mentioned below)
Details of fund materially in deficit	Para 1.24	The Charity has a long-term interest-free loan from related party Price Jones Ltd which is repayable at £2,500pa. The balance at June 2025 is £12,672.
Explanation of any uncertainties about the charity continuing as a going concern	Para 1.23	There are no current uncertainties regarding the charity continuing as a going concern.

**Additional information (optional)**

You may choose to include further statements where relevant about:

The charity's principal sources of funds (including any fundraising)	Para 1.47	The Charity's main source of funds for this reporting period were:
--	-----------	--

		<ol style="list-style-type: none"> <li>1. Public Donations via online giving and community events.</li> <li>2. Corporate donations</li> <li>3. Legacies</li> </ol>
Investment policy and objectives including any social investment policy adopted	Para 1.46	We do not currently hold enough reserves to warrant an investment policy.

A description of the principal risks facing the charity	Para 1.46	<p><b>Current Challenges</b></p> <ol style="list-style-type: none"> <li>1. <b>Balancing growth with financial constraints</b> – expanding services while managing limited resources.</li> <li>2. <b>Strained fundraising environment</b> – cost-of-living crisis and economic uncertainty making donor engagement and income generation more difficult.</li> <li>3. <b>Maintaining beneficiary engagement</b> – ensuring patients and service users remain actively involved in services and organisational development.</li> <li>4. <b>Strengthening governance structures</b> – adapting policies and oversight to match organisational growth and complexity.</li> <li>5. <b>Navigating a shifting political and health landscape</b> – responding to policy changes and advocacy needs in an unpredictable environment both nationally and geopolitically.</li> <li>6. <b>Healthcare system pressures</b> – ongoing crisis in cancer service delivery, compounded by workforce strikes, excessive bureaucracy, leadership gaps, and minimal investment.</li> <li>7. <b>Keeping pace with technology and AI</b> – leveraging digital tools and artificial intelligence for service delivery, fundraising, and communications while managing costs, skills gaps, and ethical considerations.</li> </ol>
---	-----------	---

Other		<b>Future initiatives</b> <ol style="list-style-type: none"> <li><b>Implement Year One of the 2025–2028 Strategic Plan</b>, setting the foundation for long-term impact.</li> <li><b>Develop new income generation streams</b> to strengthen financial sustainability and support service growth.</li> <li><b>Engage with the new Cancer Control Plan</b>, ensuring our approach is evidence-based and data-driven.</li> <li><b>Deliver new patient information resources</b>, including comprehensive skin-care guidelines and a major project on internal radiotherapy.</li> <li><b>Expand collaboration with like-minded organisations</b>, nationally and internationally, to amplify reach and influence.</li> <li><b>Continue campaigning and advocacy efforts</b> to secure improved access to high-quality radiotherapy services across the UK.</li> <li><b>Strengthen workforce engagement</b> through the continued growth of our Workforce Ambassadors Programme, supporting professional development and advocacy.</li> <li><b>Advance the APPG-RT programme of work</b>, with a focus on tackling inequalities in access to radiotherapy services.</li> <li><b>Collaborate with research partners across all areas</b>, including projects aimed at improving patient experience and supporting the adoption of new radiotherapy techniques.</li> </ol>

## Structure, Governance and Management

<b>Description of charity's trusts:</b>		
<b>Type of governing document (trust deed, royal charter)</b>	Para 1.25	Constitution
<b>How is the charity constituted? (e.g. unincorporated association, CIO)</b>	Para 1.25	Association
<b>Trustee selection methods including details of any constitutional provisions e.g. election to post or name of any person or body entitled to appoint one or more trustees</b>	Para 1.25	Original Trustees were nominated and elected by the ACORRN Scientific Steering Committee. New Trustees are nominated by the same process and are elected by consensus of the Board of Trustees of Radiotherapy UK.



## Reference and Administrative details

Charity name	Radiotherapy UK (previously Action Radiotherapy)
Other name the charity uses	ACORRN
Registered charity number	1135902
Charity's principal address	4 Abbotsbury House 139 Abbotsbury Road London W14 8EN

### Names of the charity trustees who manage the charity

	Trustee name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
1	Professor Patricia Price	Chair		Board of Trustees
2	Dr Christy Goldsmith	Secretary		Board of Trustees
3	Ms Tanya Levine	Treasurer		Board of Trustees
4	Dr Clive Harmer		Resigned 1.2.25	Board of Trustees
5	Professor Philip Mayles			Board of Trustees
6	Victoria Chapman		Appointed 12.9.24	Board of Trustees
7	Samina Hussain		Appointed 12.9.24	Board of Trustees
8	Professor Andrew Beavis		Appointed 12.9.24	Board of Trustees
9	Adele Lyons		Appointed 12.9.24	Board of Trustees
10	Andy Tudor		Appointed 12.9.24	Board of Trustees
11	Dr Clare Louise Hague		Appointed 12.9.24	Board of Trustees

### Funds held as custodian trustees on behalf of others

Description of the assets held in this capacity	None
Name and objects of the charity on whose behalf the assets are held and how this falls within the custodian charity's objects	None
Details of arrangements for safe custody and segregation of such assets from the charity's own assets	None

### Additional information (optional)

#### Names and addresses of advisers (Optional information)

Type of adviser	Name	Address

**Name of chief executive or names of senior staff members (Optional information)**

Sarah Quinlan – Charity Director

**Exemptions from disclosure**


Reason for non-disclosure of key personnel details

**Other optional information**

**Declarations**

The trustees declare that they have approved the trustees' report above.

Signed on behalf of the charity's trustees

Signature(s)		
Full name(s)	Professor Pat Price	
Position (e.g. Secretary, Chair, etc	Chair	
Date	16 December 2025	



## Receipts and pay

For the period from

23.06.2024

### Section A Receipts and payments

	Unrestricted funds	Restricted funds
	to the nearest £	to the nearest £
<b>A1 Receipts</b>		
Corporate donations	156,167	-
Community	22,814	-
Trusts & Foundations	5,599	-
Legacies	30,000	-
Interest Income	31	-
	-	-
	-	-
<b>Sub total</b> (Gross income for AR)	214,611	-
<b>A2 Asset and investment sales, (see table).</b>		
	-	-
	-	-
<b>Sub total</b>	-	-
<b>Total receipts</b>	214,611	-

### A3 Payments

Advocacy & campaigning	22,018	-
Charity running costs	4,690	-
Communications	5,550	-
Contractors	76,071	-
Income generation	89	-
IT & development	2,250	-
Patient services	920	-
Professional fees	5,105	-
Promotional materials	2,979	-
Research & Data analytics	-	-
Salaries	73,431	-
Workforce services	2,248	-
Training & development	3,807	-
Loan repayment	2,500	-
<b>Sub total</b>	201,658	-

### A4 Asset and investment purchases, (see table)

Computer equipment	-	-
	-	-

<b>Sub total</b>	-	-
<b>Total payments</b>	201,658	-
<b>Net of receipts/(payments)</b>	12,953	-
A5 Transfers between funds	-	-
A6 Cash funds last year end	150,624	-
<b>Cash funds this year end</b>	163,577	-

Section B Statement of assets and liabilities at the end

Categories	Details
<b>B1 Cash funds</b>	<div>Bank</div> <div></div> <div></div> <div></div> <div><b>Total cash funds</b></div>
	(agree balances with receipts and payments account(s))

<b>B2 Other monetary assets</b>	<div>Details</div> <div></div> <div></div> <div></div> <div></div> <div></div> <div></div>
---------------------------------	--

<b>B3 Investment assets</b>	<div>Details</div> <div></div> <div></div> <div></div> <div></div> <div></div>
-----------------------------	--

<b>B4 Assets retained for the charity's own use</b>	<div>Details</div> <div></div> <div></div> <div></div>
---	--


**B5 Liabilities**

**Details**

Loan due to Professor Pat Price Limited

Signed by one or two trustees on behalf of  
all the trustees

Signature


	1135902	CC16a
ments accounts		
To	22.06.2025	



Endowment funds	Total funds	Last year
to the nearest £	to the nearest £	to the nearest £
-	156,167	91,431
-	22,814	23,208
-	5,599	2,470
-	30,000	
-	31	-
-	-	-
-	-	-
-	214,611	117,110

-	-	
-	-	-
-	-	-
-	214,611	117,110

-	22,018	11,537
-	4,690	5,626
-	5,550	8,318
-	76,071	60,127
-	89	1,409
-	2,250	5,734
-	920	629
-	5,105	3,708
-	2,979	823
-	-	7,200
-	73,431	53,617
-	2,248	255
-	3,807	30
-	2,500	2,500
-	201,658	161,511

-	-	1,247
-	-	

-	-	1,247
-	201,658	162,758
-	12,953	- 45,650
-	-	-
-	150,624	196,275
-	163,577	150,625

## of the period

Unrestricted funds	Restricted funds	Endowment funds
to nearest £	to nearest £	to nearest £
	-	-
-	-	-
-	-	-
163,577	-	-
OK	OK	OK

Unrestricted funds	Restricted funds	Endowment funds
to nearest £	to nearest £	to nearest £
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-

Fund to which asset belongs	Cost (optional)	Current value (optional)
	-	-
	-	-
	-	-
	-	-
	-	-

Fund to which asset belongs	Cost (optional)	Current value (optional)
	-	-
	-	-
	-	-

	-	-
	-	-
	-	-
	-	-
	-	-
	-	-

Fund to which liability relates	Amount due (optional)	When due (optional)
	12,672	
	-	
	-	
	-	
	-	

Print Name	Date of approval



## **Independent Examiner's Report to the Trustees of Radiotherapy UK**

I report to the trustees on my examination of the accounts of Radiotherapy UK for the year ended 22 June 2025.

### **Responsibilities and basis of report**

As the charity trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011. ('the Act').

I report in respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

### **Independent examiner's statement**

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. Accounting records were not kept in respect of the Trust as required by section 130 of the Act; or
2. The accounts do not accord with those records.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report to enable a proper understanding of the accounts to be reached.



Susan Redmond FCA  
DJH Manchester Limited  
St George's House  
56 Peter Street  
Manchester  
M2 3NQ

9<sup>th</sup> January 2026

**RADIOTHERAPY UK**  
**YEAR ENDED 22 JUNE 2025**  
**NOTES TO ACCOUNTS**

**Interest-free loan**

The charity received an interest-free loan from Price Jones Limited, a company in which one of the trustees Professor Patricia Price is a director and shareholder. The loan currently stands at £12,672 and is repayable at £2,500 per annum beginning 1 July 2017.

**Related party transactions**

During the year there was a further £2,374 (2024: £4,676) paid to Professor Pat Price Limited. These were for general administrative costs. All transactions were considered to be at arm's length.

During the year donations of £38,017 (2024:£40,000) were received from Radiotherapy4Life Limited, a company in which one of the trustees Patricia Price is a director and shareholder. Donations of £5,000 were received from Professor Pat Price Limited, a company in which Patricia Price is also a director.